ClinicalTrials.gg
CompletedNCT05696080STRIDE-8Updated Mar 3, 2026Results posted

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

A Phase 3 interventional study of V116 and Placebo in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 44 sites in 8 countries. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
518
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
7th of 10
518 · median 1,075
Started
2023
with 1 other
Phase 3
9 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 7th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination within each vaccination group separately.

03

Conditions studied

  • Pneumococcal Infection
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has documented result(s) of ≥1 of the following risk conditions for pneumococcal disease: diabetes mellitus, receiving treatment with ≥1 approved antidiabetic medication, with all (HbA1c) measurements ≤9% within 6 months before first study vaccination; compensated chronic liver disease; diagnosis of (COPD) managed per local guidelines; diagnosis of mild or moderate persistent asthma managed per local guidelines; confirmed diagnosis of chronic heart disease managed per local guidelines; confirmed diagnosis of chronic kidney disease (>3 months duration).
  • Is receiving stable medical management for the listed risk conditions for ≥3 months with no anticipated major change in treatment expected for the duration of the study and with ≤1 hospitalization directly related to the risk condition.
  • Female Is not a participant of (POCBP); or if a POCBP Uses an acceptable method or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis); their medical history, menstrual history, and recent sexual activity has been reviewed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Has a history of active hepatitis.
  • Has a history of diabetic ketoacidosis or 2 or more episodes of severe, symptomatic hypoglycemia within 3 months before first study vaccination (Day 1).
  • Has a history of myocardial infarction, acute coronary syndrome, , or ischemic or hemorrhagic stroke within 3 months before first study vaccination (Day 1).
  • Has a history of severe pulmonary hypertension with World Health Organization (WHO) functional class ≥3 or history of Eisenmenger syndrome
  • Has a history of related chronic kidney disease, chronic kidney failure, a reversible cause of kidney disease, nephrotic syndrome, or any ineligible Kidney Disease: Improving Global Outcomes (KDIGO)-recommended stage of (GFR) and Albuminuria
  • Has a history of invasive pneumococcal disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years before first study vaccination (Day 1).
  • Has a known to any component of V116, PCV15, or PPSV23, including diphtheria toxoid.
  • Has a known or suspected impairment of immunological function including, but not limited to, congenital or acquired immunodeficiency, documented (HIV) infection, functional or anatomic asplenia, or autoimmune disease.
  • Has a coagulation disorder contraindicating intramuscular (IM) vaccination.
  • Had a recent febrile illness or received antibiotic therapy for any acute illness occurring within 72 hours before receipt of any study vaccine.
  • Has a known that is progressing or has required active treatment \<3 years before randomization.
  • Has planned organ transplantation (heart, liver, lung, kidney, or pancreas) or other planned major surgical procedure during the duration of this study.
  • Has expected survival for \<1 year.
  • Has received any prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol.
  • Has received systemic (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine at Visit 2 (Day 1).
  • Is currently receiving systemic therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
  • Has received any non- ≤14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine.
  • Has received any live virus vaccine (including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) live virus vaccines) ≤30 days before receipt of any study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of any study vaccine
  • Has received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of any study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of any study vaccine.
  • Is receiving chronic home oxygen therapy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
518 participants (actual)

Study arms

  • Experimental
    V116 + Placebo

    Participants administered a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo on Week 8.

    Biological: V116 · Biological: Placebo

  • Active comparator
    PCV15 + PPSV23

    Participants administered a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.

    Biological: PCV15 · Biological: PPSV23

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPlacebo

    Saline in each 0.5 mL sterile solution

  • BiologicalPCV15

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

    Also known as: VAXNEUVANCE™

  • BiologicalPPSV23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

    Also known as: PNEUMOVAX™23

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs was assessed following any vaccination. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.

    Time frame: Up to 5 days following each vaccination

  2. Participants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccination

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature \>= 100.4 °F/38.0 °C).

    Time frame: Up to 5 days following each vaccination

  3. Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study

    A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, which is determined by the investigator to be related to the vaccine. The percentage of participants with SAEs was assessed following any vaccination.

    Time frame: Up to 194 days following Visit 2 (Day 1)

  4. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116

    The serotype specific OPA GMTs for the pneumococcal serotypes were determined using the multiplex opsonophagocytic assay (MOPA). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

    Time frame: 30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.

Secondary outcomes

  1. Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Pneumococcal Serotypes Contained in V116

    The serotype specific IgG GMCs for the pneumococcal serotypes were determined using pneumococcal electrochemiluminescence assay (PnECL). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

    Time frame: 30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.

  2. Serotype-specific Geometric Mean Fold Rises (GMFRs) for OPA Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23

    The geometric mean fold rise (GMFR) from baseline to post-vaccination in serotype specific OPA GMTs was determined using MOPA. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

    Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)

  3. Serotype-specific GMFRs for IgG Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23

    The GMFR from baseline to post-vaccination in serotype specific IgG GMCs was determined using Pn electrochemiluminescence (ECL) assay. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

    Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)

  4. Percentage of Participants With ≥4-fold Change From Baseline to Post-vaccination With V116 and PCV15 + PPSV23 in Serotype Specific OPA Responses for Pneumococcal Serotypes Contained in V116

    The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using MOPA. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

    Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)

  5. Percentage of Participants With ≥4-fold Change From Baseline to Post-Vaccination With V116 and PCV15 + PPSV23 in Serotype Specific IgG Responses for Pneumococcal Serotypes Contained in V116

    The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using Pn ECL assay. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

    Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)

07

Results

Posted Feb 26, 2025

Participant flow

Pneumococcal vaccine-naïve adults 18 to 64 years of age (inclusive) with increased risk of pneumococcal disease were enrolled in this study. Participants must have had documented results of ≥ 1 of the following risk conditions: diabetes mellitus, chronic heart disease, chronic kidney disease, chronic liver disease, and/or chronic lung disease. Participants with comorbidities were eligible if the conditions were assessed to be stable as per the investigator's judgment.

Participant flow — Overall Study
MilestoneV116 + PlaceboPCV15 + PPSV23
Started387131
Vaccinated with v116 at visit 23860
Vaccinated with pcv15 at visit 20130
Vaccinated with placebo at visit 53740
Vaccinated with ppsv23 at visit 50128
Completed372129
Not completed152
Withdrew: Lost to follow-up21
Withdrew: Physician decision10
Withdrew: Randomized by mistake without study treatment01
Withdrew: Withdrawal by subject120

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs was assessed following any vaccination. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.

Time frame:
Up to 5 days following each vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination
Percentage of participantsV116 + PlaceboPCV15 + PPSV23
Injection site erythema9.1 (6.4 to 12.4)25.4 (18.2 to 33.8)
Injection site pain51.8 (46.7 to 56.9)78.5 (70.4 to 85.2)
Injection site swelling8.0 (5.5 to 11.2)35.4 (27.2 to 44.2)
PrimaryParticipants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccination

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature \>= 100.4 °F/38.0 °C).

Time frame:
Up to 5 days following each vaccination
Reported as:
Number · Percentage of participants
Participants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccination
Percentage of participantsV116 + PlaceboPCV15 + PPSV23
Fatigue30.3 (25.8 to 35.2)45.4 (36.6 to 54.3)
Headache22.3 (18.2 to 26.8)26.2 (18.8 to 34.6)
Myalgia10.9 (8.0 to 14.4)15.4 (9.7 to 22.8)
Pyrexia3.1 (1.6 to 5.4)4.6 (1.7 to 9.8)
PrimaryParticipants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study

A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, which is determined by the investigator to be related to the vaccine. The percentage of participants with SAEs was assessed following any vaccination.

Time frame:
Up to 194 days following Visit 2 (Day 1)
Reported as:
Number · Percentage of participants
Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study
Percentage of participantsV116 + PlaceboPCV15 + PPSV23
Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study0.0 (0.0 to 1.0)0.0 (0.0 to 2.8)
PrimarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116

The serotype specific OPA GMTs for the pneumococcal serotypes were determined using the multiplex opsonophagocytic assay (MOPA). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Time frame:
30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.
Reported as:
Geometric mean · Titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116
TitersV116 + PlaceboPCV15 + PPSV23
Serotype 3216.2 (188.6 to 247.8)192.9 (156.7 to 237.4)
Serotype 6A3734.9 (3204.3 to 4353.4)2443.8 (1779.0 to 3357.1)
Serotype 7F4261.2 (3781.6 to 4801.6)3218.5 (2627.3 to 3942.6)
Serotype 83460.8 (3083.1 to 3884.7)3406.4 (2635.8 to 4402.2)
Serotype 9N7553.9 (6664.1 to 8562.5)4548.4 (3696.8 to 5596.2)
Serotype 10A4502.0 (3933.7 to 5152.4)2542.0 (1897.0 to 3406.2)
Serotype 11A3761.7 (3375.8 to 4191.7)1697.2 (1338.4 to 2152.2)
Serotype 12F2432.3 (2082.7 to 2840.6)1364.5 (956.1 to 1947.4)
Serotype 17F10425.3 (9099.2 to 11944.7)4331.7 (3248.3 to 5776.3)
Serotype 19A2837.2 (2535.2 to 3175.2)2437.2 (2008.5 to 2957.5)
Serotype 20A8091.5 (7169.4 to 9132.3)3749.8 (2932.4 to 4795.2)
Serotype 22F4432.7 (3914.2 to 5020.0)2717.4 (2201.7 to 3353.8)
Serotype 33F24512.8 (21149.8 to 28410.7)11395.1 (8884.5 to 14615.3)
Serotype 15A7274.6 (6398.7 to 8270.4)1791.8 (1361.7 to 2357.8)
Serotype 15C7923.1 (6726.7 to 9332.3)2269.8 (1651.8 to 3118.9)
Serotype 16F9546.6 (8396.2 to 10854.6)1626.2 (1224.4 to 2159.8)
Serotype 23A5875.3 (5005.5 to 6896.2)1493.9 (1009.1 to 2211.5)
Serotype 23B2316.9 (1925.9 to 2787.3)117.0 (73.4 to 186.4)
Serotype 24F5677.1 (5098.2 to 6321.8)1666.8 (1257.6 to 2209.1)
Serotype 315803.9 (4991.8 to 6748.1)360.7 (233.0 to 558.5)
Serotype 35B13141.3 (11584.8 to 14906.9)1812.1 (1408.6 to 2331.2)
SecondarySerotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Pneumococcal Serotypes Contained in V116

The serotype specific IgG GMCs for the pneumococcal serotypes were determined using pneumococcal electrochemiluminescence assay (PnECL). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Time frame:
30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.
Reported as:
Geometric mean · μg/mL
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Pneumococcal Serotypes Contained in V116
μg/mLV116 + PlaceboPCV15 + PPSV23
Serotype 30.77 (0.69 to 0.87)0.79 (0.68 to 0.92)
Serotype 6A4.57 (3.82 to 5.48)5.83 (4.23 to 8.03)
Serotype 7F8.77 (7.65 to 10.06)6.95 (5.39 to 8.96)
Serotype 810.20 (8.89 to 11.71)12.50 (9.68 to 16.14)
Serotype 9N7.53 (6.42 to 8.83)4.35 (3.35 to 5.66)
Serotype 10A12.18 (10.36 to 14.32)6.88 (5.07 to 9.34)
Serotype 11A7.78 (6.80 to 8.89)4.04 (3.22 to 5.07)
Serotype 12F1.90 (1.58 to 2.28)0.84 (0.60 to 1.18)
Serotype 17F17.35 (15.06 to 19.98)8.20 (6.32 to 10.64)
Serotype 19A9.11 (7.98 to 10.41)10.88 (8.70 to 13.60)
Serotype 20A19.51 (16.73 to 22.75)13.38 (10.27 to 17.43)
Serotype 22F5.17 (4.44 to 6.02)3.98 (3.08 to 5.14)
Serotype 33F15.38 (13.23 to 17.88)11.40 (8.99 to 14.46)
Serotype 15A14.65 (12.52 to 17.13)2.37 (1.77 to 3.18)
Serotype 15C14.48 (12.07 to 17.38)5.42 (3.98 to 7.37)
Serotype 16F2.90 (2.48 to 3.38)0.27 (0.21 to 0.35)
Serotype 23A3.85 (3.18 to 4.66)0.79 (0.56 to 1.11)
Serotype 23B6.62 (5.75 to 7.63)1.46 (1.09 to 1.96)
Serotype 24F5.18 (4.17 to 6.43)0.34 (0.26 to 0.43)
Serotype 313.27 (2.83 to 3.79)0.38 (0.29 to 0.49)
Serotype 35B19.78 (17.38 to 22.50)1.55 (1.27 to 1.90)
SecondarySerotype-specific Geometric Mean Fold Rises (GMFRs) for OPA Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23

The geometric mean fold rise (GMFR) from baseline to post-vaccination in serotype specific OPA GMTs was determined using MOPA. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Time frame:
Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Reported as:
Geometric mean · Ratio
Serotype-specific Geometric Mean Fold Rises (GMFRs) for OPA Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23
RatioV116 + PlaceboPCV15 + PPSV23
Serotype 38.3 (7.2 to 9.5)6.1 (4.8 to 7.7)
Serotype 6A22.8 (18.6 to 28.0)17.1 (11.9 to 24.7)
Serotype 7F20.4 (16.9 to 24.6)10.5 (7.5 to 14.7)
Serotype 825.7 (21.1 to 31.2)25.2 (17.0 to 37.1)
Serotype 9N12.6 (10.6 to 15.0)7.2 (5.5 to 9.5)
Serotype 10A19.9 (16.1 to 24.5)10.7 (7.2 to 15.8)
Serotype 11A20.7 (16.6 to 25.8)6.8 (4.6 to 10.1)
Serotype 12F95.0 (79.9 to 113.0)48.6 (32.5 to 72.6)
Serotype 17F28.4 (23.6 to 34.2)13.1 (9.5 to 18.1)
Serotype 19A9.7 (8.2 to 11.5)9.9 (7.2 to 13.6)
Serotype 20A8.5 (7.2 to 10.0)3.8 (3.0 to 5.0)
Serotype 22F15.1 (12.2 to 18.7)9.1 (6.0 to 13.7)
Serotype 33F12.3 (10.4 to 14.5)5.5 (4.1 to 7.2)
Serotype 15A10.4 (8.6 to 12.5)2.4 (1.8 to 3.2)
Serotype 15C52.8 (42.1 to 66.2)18.3 (12.2 to 27.4)
Serotype 16F8.6 (7.3 to 10.1)1.6 (1.2 to 2.0)
Serotype 23A14.5 (11.4 to 18.6)4.3 (2.7 to 6.8)
Serotype 23B83.6 (66.4 to 105.3)6.2 (4.3 to 9.0)
Serotype 24F4.0 (3.4 to 4.7)0.9 (0.7 to 1.2)
Serotype 3123.2 (18.4 to 29.1)1.5 (1.2 to 2.0)
Serotype 35B7.2 (6.3 to 8.3)1.2 (1.0 to 1.4)
SecondarySerotype-specific GMFRs for IgG Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23

The GMFR from baseline to post-vaccination in serotype specific IgG GMCs was determined using Pn electrochemiluminescence (ECL) assay. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Time frame:
Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Reported as:
Geometric mean · Ratio
Serotype-specific GMFRs for IgG Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23
RatioV116 + PlaceboPCV15 + PPSV23
Serotype 35.2 (4.7 to 5.8)4.5 (3.8 to 5.4)
Serotype 6A16.2 (13.9 to 18.9)20.1 (15.5 to 26.0)
Serotype 7F19.0 (16.8 to 21.5)12.8 (10.2 to 16.2)
Serotype 814.8 (12.9 to 17.0)15.5 (11.5 to 21.0)
Serotype 9N19.2 (16.8 to 22.0)9.9 (7.9 to 12.5)
Serotype 10A20.1 (17.6 to 23.0)11.0 (8.6 to 13.9)
Serotype 11A11.7 (10.3 to 13.3)5.6 (4.5 to 7.0)
Serotype 12F17.7 (15.3 to 20.5)8.1 (6.2 to 10.6)
Serotype 17F29.6 (25.9 to 33.8)13.9 (10.9 to 17.6)
Serotype 19A7.1 (6.3 to 8.0)8.1 (6.5 to 10.0)
Serotype 20A15.1 (13.2 to 17.2)8.7 (7.0 to 10.8)
Serotype 22F19.7 (17.0 to 22.8)13.2 (10.2 to 17.3)
Serotype 33F14.7 (13.0 to 16.6)11.0 (8.8 to 13.8)
Serotype 15A23.6 (20.6 to 27.1)3.7 (3.0 to 4.6)
Serotype 15C24.2 (20.8 to 28.2)9.2 (7.3 to 11.7)
Serotype 16F16.0 (14.1 to 18.1)1.6 (1.4 to 1.9)
Serotype 23A20.9 (18.2 to 24.0)3.8 (2.9 to 4.9)
Serotype 23B16.6 (14.3 to 19.2)3.7 (3.0 to 4.6)
Serotype 24F18.0 (15.5 to 20.9)1.1 (1.1 to 1.2)
Serotype 3114.4 (12.7 to 16.4)1.5 (1.4 to 1.7)
Serotype 35B12.8 (11.3 to 14.5)1.0 (1.0 to 1.1)
SecondaryPercentage of Participants With ≥4-fold Change From Baseline to Post-vaccination With V116 and PCV15 + PPSV23 in Serotype Specific OPA Responses for Pneumococcal Serotypes Contained in V116

The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using MOPA. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Time frame:
Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Change From Baseline to Post-vaccination With V116 and PCV15 + PPSV23 in Serotype Specific OPA Responses for Pneumococcal Serotypes Contained in V116
Percentage of ParticipantsV116 + PlaceboPCV15 + PPSV23
Serotype 370.1 (64.8 to 74.9)63.7 (53.6 to 73.0)
Serotype 6A79.1 (74.1 to 83.6)79.3 (68.9 to 87.4)
Serotype 7F78.3 (73.5 to 82.6)63.6 (53.7 to 72.6)
Serotype 884.6 (80.3 to 88.2)82.5 (73.8 to 89.3)
Serotype 9N74.7 (69.7 to 79.3)58.9 (49.0 to 68.3)
Serotype 10A74.9 (69.9 to 79.5)70.4 (60.3 to 79.2)
Serotype 11A76.7 (71.7 to 81.2)49.0 (38.9 to 59.2)
Serotype 12F94.2 (91.1 to 96.4)85.0 (76.9 to 91.2)
Serotype 17F89.6 (85.8 to 92.7)76.2 (66.7 to 84.1)
Serotype 19A68.0 (62.7 to 72.9)68.6 (58.7 to 77.5)
Serotype 20A66.9 (61.5 to 71.9)42.3 (32.3 to 52.7)
Serotype 22F74.8 (69.7 to 79.5)57.8 (47.7 to 67.6)
Serotype 33F78.5 (73.7 to 82.8)58.0 (47.7 to 67.8)
Serotype 15A67.6 (62.1 to 72.8)29.5 (20.6 to 39.7)
Serotype 15C86.0 (81.8 to 89.5)72.4 (62.8 to 80.7)
Serotype 16F65.6 (60.2 to 70.7)16.7 (9.8 to 25.6)
Serotype 23A71.3 (65.4 to 76.7)52.6 (40.8 to 64.2)
Serotype 23B87.7 (83.7 to 91.0)49.1 (39.2 to 59.0)
Serotype 24F41.6 (35.9 to 47.5)6.2 (2.0 to 13.8)
Serotype 3177.0 (72.2 to 81.4)16.2 (9.5 to 24.9)
Serotype 35B64.4 (59.0 to 69.5)5.9 (2.2 to 12.4)
SecondaryPercentage of Participants With ≥4-fold Change From Baseline to Post-Vaccination With V116 and PCV15 + PPSV23 in Serotype Specific IgG Responses for Pneumococcal Serotypes Contained in V116

The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using Pn ECL assay. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.

Time frame:
Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Change From Baseline to Post-Vaccination With V116 and PCV15 + PPSV23 in Serotype Specific IgG Responses for Pneumococcal Serotypes Contained in V116
Percentage of ParticipantsV116 + PlaceboPCV15 + PPSV23
Serotype 357.8 (52.6 to 62.9)54.1 (44.3 to 63.6)
Serotype 6A81.1 (76.8 to 85.0)86.5 (78.7 to 92.2)
Serotype 7F88.8 (85.1 to 91.8)83.8 (75.6 to 90.1)
Serotype 882.2 (77.9 to 86.0)83.8 (75.6 to 90.1)
Serotype 9N86.9 (83.0 to 90.2)78.4 (69.6 to 85.6)
Serotype 10A86.3 (82.4 to 89.7)79.3 (70.5 to 86.4)
Serotype 11A79.8 (75.3 to 83.8)63.1 (53.4 to 72.0)
Serotype 12F82.8 (78.5 to 86.5)69.4 (59.9 to 77.8)
Serotype 17F93.2 (90.1 to 95.5)82.9 (74.6 to 89.4)
Serotype 19A64.2 (59.1 to 69.1)73.0 (63.7 to 81.0)
Serotype 20A83.1 (78.8 to 86.8)75.7 (66.6 to 83.3)
Serotype 22F85.0 (80.9 to 88.5)83.8 (75.6 to 90.1)
Serotype 33F87.2 (83.3 to 90.4)79.3 (70.5 to 86.4)
Serotype 15A88.3 (84.5 to 91.4)44.1 (34.7 to 53.9)
Serotype 15C88.5 (84.8 to 91.6)75.5 (66.3 to 83.2)
Serotype 16F85.8 (81.8 to 89.2)7.3 (3.2 to 13.8)
Serotype 23A88.3 (84.5 to 91.4)37.8 (28.8 to 47.5)
Serotype 23B81.7 (77.3 to 85.5)43.2 (33.9 to 53.0)
Serotype 24F82.0 (77.6 to 85.8)2.7 (0.6 to 7.7)
Serotype 3183.1 (78.8 to 86.8)9.9 (5.1 to 17.0)
Serotype 35B79.5 (75.0 to 83.5)0.9 (0.0 to 4.9)

Adverse events

Collected over Up to ~ 194 Days following Visit 2 (Day 1). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V116 + Placebo0/387 (0%)10/386 (2.6%)240/386 (62.2%)
PCV15 + PPSV230/131 (0%)7/130 (5.4%)112/130 (86.2%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventV116 + PlaceboPCV15 + PPSV23
Coronary artery stenosisCardiac disorders0/3861/130
Ventricular tachycardiaCardiac disorders0/3861/130
Pancreatitis acuteGastrointestinal disorders0/3861/130
Pneumonia bacterialInfections and infestations0/3861/130
SeizureNervous system disorders0/3861/130
SyncopeNervous system disorders0/3861/130
Acute kidney injuryRenal and urinary disorders0/3861/130
Deep vein thrombosisVascular disorders0/3861/130
Gastrooesophageal reflux diseaseGastrointestinal disorders1/3860/130
Obstructive pancreatitisGastrointestinal disorders1/3860/130
Most frequent other events
Most frequent other events
EventV116 + PlaceboPCV15 + PPSV23
Injection site painGeneral disorders200/386102/130
FatigueGeneral disorders118/38659/130
Injection site swellingGeneral disorders33/38646/130
HeadacheNervous system disorders94/38636/130
Injection site erythemaGeneral disorders39/38633/130
MyalgiaMusculoskeletal and connective tissue disorders42/38620/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V116 + PlaceboPCV15 + PPSV23Total
Mean52.4 ± 9.653.3 ± 8.952.6 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)V116 + PlaceboPCV15 + PPSV23Total
Female17855233
Male20976285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V116 + PlaceboPCV15 + PPSV23Total
Hispanic or Latino10135136
Not Hispanic or Latino28194375
Unknown or Not Reported527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V116 + PlaceboPCV15 + PPSV23Total
American Indian or Alaska Native101
Asian581876
Native Hawaiian or Other Pacific Islander10818
Black or African American16218
White294101395
More than one race8210
Unknown or Not Reported000
08

Study locations

44 sites
  • Aventiv Research ( Site 0022)
    Mesa, Arizona 85206, United States
  • Indago Research & Health Center, Inc ( Site 0002)
    Hialeah, Florida 33012, United States
  • Triple O Research Institute, P.A ( Site 0011)
    West Palm Beach, Florida 33407, United States
  • SKY Integrative Medical Center/SKYCRNG ( Site 0012)
    Ridgeland, Mississippi 39157, United States
  • Mid Hudson Medical Research ( Site 0008)
    New Windsor, New York 12553, United States
  • Holston Medical Group ( Site 0010)
    Kingsport, Tennessee 37660, United States
  • EmVenio Research ( Site 0018)
    Fort Worth, Texas 27713, United States
  • Wenatchee Valley Hospital ( Site 0019)
    Wenatchee, Washington 98801, United States
  • Holdsworth House Medical Practice ( Site 0402)
    Darlinghurst, New South Wales 2010, Australia
  • Royal Brisbane and Women's Hospital ( Site 0400)
    Brisbane, Queensland 4029, Australia
  • G A Research Associates ( Site 0100)
    Moncton, New Brunswick E1G 1A7, Canada
  • Hamilton Medical Research Group ( Site 0107)
    Hamilton, Ontario L8M 1K7, Canada
  • Milestone Research Inc. ( Site 0106)
    London, Ontario N5W 6A2, Canada
  • Manna Research Mirabel ( Site 0105)
    Mirabel, Quebec J7J 2K8, Canada
  • Clinique de médecine Urbaine du Quartier Latin ( Site 0111)
    Montreal, Quebec H2L 4E9, Canada
  • Diex Recherche Trois-Rivieres ( Site 0110)
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Diex Recherche Victoriavile Inc. ( Site 0102)
    Victoriaville, Quebec G6P 6P6, Canada
  • Hospital Dr. Hernán Henríquez Aravena ( Site 1001)
    Temuco, Araucania 4781151, Chile
  • Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010)
    Talca, Maule Region 3460000, Chile
  • Universidad San Sebastian - Providencia ( Site 1003)
    Providencia, Region M. de Santiago 7500000, Chile
  • Centro de Investigaciones Medicas Respiratorias (CIMER) ( Site 1008)
    Santiago, Region M. de Santiago 7500692, Chile
  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 1004)
    Santiago, Region M. de Santiago 8330034, Chile
  • Universidad de Chile - Hospital Clínico Universidad de Chile-Cardiology ( Site 1006)
    Santiago, Region M. de Santiago 8380420, Chile
  • CESFAM Esmeralda ( Site 1009)
    Santiago, Region M. de Santiago 9340000, Chile
  • Medical corporation Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic ( Site 0200)
    Kurume, Fukuoka 830-0011, Japan
  • Shimonoseki Medical Center ( Site 0201)
    Shimonoseki, Yamaguchi 750-0061, Japan
  • Pacific Clinical Research Network - Rotorua ( Site 0500)
    Rotorua, Bay of Plenty 3010, New Zealand
  • P3 Research - Tauranga ( Site 0507)
    Tauranga, Bay of Plenty 3110, New Zealand
  • CGM Research Trust ( Site 0505)
    Christchurch, Canterbury 8011, New Zealand
  • Pacific Clinical Research Network - Forte ( Site 0501)
    Christchurch, Canterbury 8013, New Zealand
  • P3 Research - Lower Hutt ( Site 0508)
    Lower Hutt, Wellington Region 5010, New Zealand
  • P3 Research - Wellington ( Site 0503)
    Wellington, 6021, New Zealand
  • IN VIVO ( Site 0601)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-048, Poland
  • Centrum Medyczne Pratia Bydgoszcz-Centrum Medyczne Pratia Bydgoszcz ( Site 0607)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • MICS Centrum Medyczne Torun ( Site 0606)
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
  • Centrum Medyczne Medyk ( Site 0602)
    Rzeszów, Podkarpackie Voivodeship 35-055, Poland
  • Centrum Medyczne Pratia Katowice ( Site 0604)
    Katowice, Silesian Voivodeship 40-081, Poland
  • Clinical Medical Research ( Site 0605)
    Katowice, Silesian Voivodeship 40-156, Poland
  • Clinmedica Research Sp. z. o. o. ( Site 0603)
    Skierniewice, Łódź Voivodeship 96-100, Poland
  • Hallym University Sacred Heart Hospital ( Site 0303)
    Anyang-si, Kyonggi-do 14068, South Korea
  • Korea University Anam Hospital ( Site 0305)
    Seoul, 02841, South Korea
  • Seoul National University Hospital ( Site 0300)
    Seoul, 03080, South Korea
  • Konkuk University Medical Center ( Site 0302)
    Seoul, 05030, South Korea
  • Hallym University Kangdong Sacred Heart Hospital ( Site 0301)
    Seoul, 05355, South Korea
09

References and documents

Publications

  • Scott PT, Pathirana J, Kato A, Tytus R, Perez CM, Gilchrist NL, Kanou H, Ha Yoo K, Kania G, Nissen M, Russell AF, Fernsler D, Waleed M, Li J, Buchwald UK, Platt HL. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naive Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. Clin Infect Dis. 2026 Feb 25;82(2):e217-e226. doi: 10.1093/cid/ciaf604. PubMed 41208546 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Feb 2024, 12 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Jan 25, 2023
StartActual
Feb 13, 2023
Primary completionActual
Feb 16, 2024
CompletionActual
Feb 16, 2024
Results first posted
Feb 26, 2025
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05696080
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Feb 13, 2023
Primary completion
Feb 16, 2024
Completion
Feb 16, 2024
Results posted
Feb 26, 2025
Last update
Mar 3, 2026

Study contacts

Clinical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion